DCM
HUMA icon

DG Capital Management’s Humacyte HUMA Stock Holding History

DG Capital Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-230,238
Closed -$716K – 23
2024
Q1 		$716K Buy
+230,238
New +$774K 0.44% 17

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

DG Capital Management's HUMA Position: Q2 2024 in Review

DG Capital Management sold out of Humacyte (HUMA) in Q2 2024, closing a stake of 230,238 shares — an estimated $716K sold.

DG Capital Management first reported a position in HUMA in Q1 2024 and held it in 1 quarter. The position peaked at $716K in Q1 2024. 123 funds tracked by Wall St. Rank hold HUMA as of Q2 2024.

  • DG Capital Management reported no remaining Humacyte position as of Q2 2024 after selling out during the quarter.
  • DG Capital Management sold 230,238 Humacyte shares in Q2 2024, an estimated $716K.
  • DG Capital Management first reported a position in Humacyte in Q1 2024 and held it in 1 quarter.
  • DG Capital Management's Humacyte position peaked at $716K in Q1 2024.
  • 123 funds tracked by Wall St. Rank held Humacyte as of Q2 2024.

Based on DG Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.